17143257Vokes E, Herbst R, Sandler AClinical advances in hematology & oncology : H&OAntineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neovascularization, PathologicAngiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor AAngiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol. 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2.Clin Adv Hematol Oncol2006-11-01T00:00:002006Angiogenesis inhibition in the treatment of lung cancer.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000971Procedures30624340.476235Antineoplastic Combined Chemotherapy ProtocolsD000911Chemicals & Drugs33713760.622749Antibodies, MonoclonalD002289Disorders15810730.519149Carcinoma, Non-Small-Cell LungD009389Disorders1303520.823558Neovascularization, PathologicD008175Disorders32822600.404525Lung NeoplasmsD012307Concepts & Ideas94153970.464223Risk FactorsD006801Living Beings2262862810.130052HumansD016032Concepts & IdeasProcedures2778500.730116Randomized Controlled Trials as TopicD016190Chemicals & Drugs802860.908369CarboplatinD017239Chemicals & Drugs1164600.850613PaclitaxelD020533Chemicals & DrugsPhysiology1073090.812499Angiogenesis InhibitorsD011799Chemicals & Drugs652200.877229QuinazolinesD061067Chemicals & Drugs2139290.656166Antibodies, Monoclonal, HumanizedD015996Concepts & Ideas45518560.724887Survival RateD017326Activities & BehaviorsProcedures741690.934989Clinical Trials, Phase III as TopicD042461Chemicals & Drugs1564070.844293Vascular Endothelial Growth Factor AD000068258732810.891431BevacizumabD00006934738900.973307Erlotinib HydrochlorideD006470Disorders1402650.843174HemorrhageD018572Concepts & Ideas25812030.792696Disease-Free SurvivalD047428Chemicals & Drugs2065890.714193Protein Kinase InhibitorsMedicineUniversity of ChicagoEverett E.VokesEverett E. Vokes41.78927490000000-87.601250000000001920Vokes, Everett E.Professortrue1ProfessorProfessorAuthorship 5665810.2992760.2992761authors10.2521has subject area